Forti-D Drug Interactions

Soft gelatin cap: 1,000 IU/Syr: 1,000 IU: If the patient is taking the following drugs, consult the doctor: Phosphate infusion, cardiac glycoside, thiazide diuretic, metabolites of vitamin D3 or vitamin D analogues, phenytoin, phenobarbital, primidone, rifampicin, isoniazid, orlistat, liquid paraffin, cholestyramine, glucocorticoid, multivitamin and mineral, calcitonin, etidronate, gallium nitrate, pamidronate, or plicamycin, calcium salt, conivaptan, aripiprazole, axitinib, saxagliptin, bile acid sequestrant, CYP3A4 inducer, deferasirox, mineral oil, orlistat, sevelamer, tocilizumab.
Soft gelatin cap: 5,000 IU: Phosphate infusions should not be administered to lower hypercalcemia of hypervitaminosis D because of the risks of metastatic calcification.
Patients who treats with cardiac glycosides may be susceptible to high calcium levels and should monitor ECG parameters and calcium levels. If the calcium level in the urine reaches 7.5 mmol/24 hours (300 mg/24 hours), the dosage should be reduced or therapy should be discontinued.
Simultaneous administration of benzothiadiazine derivatives (thiazide diuretics) increases the risk of hypercalcemia since it can decrease the calcium excretion in the urine. Patients who received long-term therapy should monitor their calcium levels in plasma and urine.
Concurrent used of Cholecalciferol with vitamin D metabolites or analogues, serum calcium levels should be closely monitored.
Anti-convulsant (e.g.: phenytoin, phenobarbital, primidone) may reduce the effect of Cholecalciferol due to hepatic enzyme induction.
Rifampicin may reduce the effectiveness of Cholecalciferol due to hepatic enzyme induction.
Isoniazid may reduce the effectiveness of Cholecalciferol since it can inhibit the metabolic activation of Cholecalciferol.
Drugs that cause fat malabsorption (e.g.: orlistat, liquid paraffin and cholestyramine) may interfere the absorption of Cholecalciferol.
The cytotoxic agent actinomycin and imidazole anti-fungal agents may interfere vitamin D activity by inhibiting the conversion of 25-hydroxycholecalciferol to 1,25-hydroxy-cholecalciferol by the renal enzyme, 25-hydroxycholecalciferol-1-hydroxylase.
Concurrent use of glucocorticoids can reduce the effectiveness of vitamin D.
Avoid taking multivitamins and minerals (Vitamin A, D, E, K, folic acid and iron), calcitonin, etidronate, gallium nitrate, pamidronate, or plicamycin at the same time.
Vitamin D can increase the levels/effects of aluminium hydroxide, cardiac glycosides, magnesium salts, sucralfate, vitamin D analogues.
Levels/effects of vitamin D can increase when administered with calcium salt and conivaptan.
Vitamin D can decrease levels/effects of aripiprazole, axitinib and saxagliptin.
Levels/effects of vitamin D can decrease when administered with bile acid sequestrant, corticosteroids (systemic), CYP3A4 inducers, deferasirox, mineral oil, orlistat, sevelamer, tocilizumab, anti-convulsant, hydantoin, barbiturates or primidone.